The company operates a hybrid business model around these activities, providing protein expression and process development services for clients, from the laboratory up to clinical trial material for use in humans: the revenues from the services side of the company partly fund the development of an internal pipeline of products in the oncology field, based around recombinant antibodies.

Biotecnol also has its own proprietary recombinant antibody platform - the "Tribody" platform. These are multifunctional recombinant antibody derivatives, which utilise the natural in vivo heterodimerization of Fd fragments and light chains of a Fab fragment, to form a scaffold, upon which additional functions can be incorporated, such as additional binders, or cytokines, chemokines, growth factors, enzymes or protein toxins.

Tribodies are being used in Biotecnol's own product pipeline development, and is also available for collaborative developments. Such collaborations can be in-house development, production and purification of recombinant Tribody constructs for R&D and development of clinical candidate products, or pursuing collaborations with partners having proprietary targets for developing early-stage clinical candidate products. Platform out-licensing is also a possibility.

Furthermore, several R&D grants, both from the Portuguese government and the European Commission, complemented the financing of the company activities. In 2000, Biotecnol attracted its first investment and was able to begin independent activities. This allowed Biotecnol to develop into the first pharmaceutical biotech research & development-driven company in Portugal.

Additional financing in 2002 allowed Biotecnol to start implementing its actual business model, and which also allowed the transition of Biotecnol from a "technology development" company to a "product development" company.

During Q1 2006, Biotecnol consolidated all its activities into the current facility, a fully integrated 800 m2 biologics development facilities and offices at Lagoas Park in Oeiras, Portugal. To further complement this, and to expand activities into North America, Biotecnol has also established a wholly-owned subsidiary, Biotecnol Pharmaceuticals Inc, in Durham, North Carolina, USA in 2008.

In addition to these activities, Biotecnol also co-founded the Portuguese Bio-Industries Association (APBio) in 1998 to promote the development of a biotechnological industry in Portugal. APBio is part of the European Bioindustries Association (EuropaBio), which represents over 600 European companies.

Anti-PTHrP antibody

Cardiotrophin-1